These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18847421)

  • 1. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J
    Nefrologia; 2008; 28 Suppl 5():53-7. PubMed ID: 18847421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM; Szeto CC; Kwan BC; Leung CB; Li PK
    J Nephrol; 2007; 20(6):674-82. PubMed ID: 18046669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with sevelamer in peritoneal dialysis].
    Ortiz A; Ríos F; Melero R; Reyero A; Gazapo R; Casado S
    Nefrologia; 2003; 23(5):432-6. PubMed ID: 14658169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
    St Peter WL; Fan Q; Weinhandl E; Liu J
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1954-61. PubMed ID: 19833904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of sevelamer in patients new to dialysis.
    Taylor MJ; Elgazzar HA; Chaplin S; Goldsmith D; Molony DA
    Curr Med Res Opin; 2008 Feb; 24(2):601-8. PubMed ID: 18205996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
    Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
    Akatsuka T; Mochizuki T; Koike T
    Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences.
    Huybrechts KF; Caro JJ; O'Brien JA
    Value Health; 2009; 12(1):16-9. PubMed ID: 18647261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.